Fibrx: New Fibrosis Biotech.
Skye Bioscience Acquires Redx Pharma, Forms Fibrx Therapeutics to Focus on Fibrotic Diseases.
Key Points
Skye Bioscience terminated all nimacimab R&D and initiated cost-cutting amid competitive pressures and suboptimal trial results, signaling a strategic shift as it pursues the Redx acquisition.
The financing package includes a side-letter backstop of up to $5 million, a binding term sheet for a $22.0 million equity line, and a $5.0 million warrant with Redmile, along with contingent value rights for legacy assets and investor lock-up/voting commitments.
Market analysts from Spark (TipRanks) rate Skye as Neutral, citing very weak financial performance (no revenue, large losses, and significant cash burn) and elevated dilution risk, plus Nasdaq compliance and listing-tier risks.
The deal is being implemented via a UK scheme of arrangement, with completion targeted for the fourth quarter of 2026, and will result in Fibrx Therapeutics trading on Nasdaq.
The financing syndicate for the deal includes Abingworth, the British Business Bank, NEXTBio Capital, and 5AM Ventures, with Abingworth leading the Series A and Redmile remaining a major shareholder providing the equity line.
Skye Bioscience and UK-based Redx Pharma have agreed to merge and create a new company called Fibrx Therapeutics, a Nasdaq-listed biotech focused on fibrotic diseases. The deal comes with a $125 million financing package and will be led by Redx's existing management team, according to Fierce Biotech and TipRanks.
The combined company will advance Redx's lead drug candidate, RXC008, a treatment for fibrotic Crohn's disease that already holds FDA Fast Track status. Completion is targeted for the fourth quarter of 2026, per TradingView.
Skye Dumps Nimacimab, Bets Big on Fibrosis
Before the deal, Skye was in trouble. The company shut down all R&D on its drug nimacimab after poor trial results and stiff competition. It also began cutting costs aggressively, according to TradingView. With no revenue and mounting losses, the company needed a new direction fast.
The Redx acquisition is that new direction. Redx brings a focused pipeline in fibrotic diseases — conditions where scar tissue builds up and damages organs. RXC008 targets that process in the gut. The new Fibrx Therapeutics will be built around these programs, with Redx's management running the show.
$125 Million Financing Package Funds Fibrx to 2029
The deal includes three parts. A $68 million PIPE — private investment in public equity — forms the bulk. A $36 million Series A led by Abingworth adds more. A $22 million equity line backed by Redmile rounds it out. The British Business Bank, NEXTBio Capital, and 5AM Ventures are also in the syndicate, per Insider Media.
Redmile also provides a $5 million warrant and a $5 million backstop side letter. These extras offer a safety net if other funding falls short. TradingView reports the full package is designed to fund Fibrx's operations through 2029 — a rare runway for a small biotech.
UK Scheme of Arrangement Shapes Deal Structure
The merger will be executed through a UK scheme of arrangement — a court-supervised legal process used for major corporate deals in Britain. When complete, shares will be split among three groups: Redx holders, legacy Skye holders, and new financing investors. Legacy Skye assets will be separated into contingent value rights, or CVRs, which pay out only if those older assets succeed, according to TipRanks.
Investors in the new financing rounds will face lock-up periods and must commit their votes to support the deal. Fibrx will also pursue Nasdaq compliance improvements and may do a reverse stock split to meet listing requirements, per TradingView.
Analysts Flag Dilution Risk and Nasdaq Compliance Hurdles
Not everyone is cheering. Spark analysts at TipRanks rate Skye as Neutral. They point to zero revenue, large ongoing losses, and heavy cash burn. The financing deal will significantly dilute existing shareholders — meaning each share is worth less as more shares are issued.
Nasdaq compliance is another concern. Skye already faces listing-tier risks and ongoing litigation. The company will need to meet stricter exchange requirements after the deal closes. Analysts say the path forward is promising but risky — Fibrx must execute in a high-stakes field where many biotechs have failed, per TipRanks.
Sentiment
Mostly PositivePublishers
10
Articles
18
Reach
28
